HCL Patient Seminar September 2014 Quality of Life Monica Else.

Slides:

Advertisements

Similar presentations

Observational study to determine the rate of occurrence of invasive mould disease and treatment outcomes in at-risk patients: a European prospective invasive.

Advertisements

Bendamustine + Rituximab (BR) Chemoimmunotherapy and Maintenance Lenalidomide in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and Small.

An Intergroup Randomised Trial of Rituximab versus a Watch & Wait Approach in Patients with Advanced Stage, Asymptomatic, Non-bulky Follicular Lymphoma.

A single centre study of the efficacy of extracorporeal photopheresis in Acute Graft Versus Host Disease Lynne Watson Nottingham University Hospital NHS.

Hairy Cell Leukemia Foundation and

Casulo C et al. Proc ASH 2013;Abstract 510.

Expression profiles for prognosis and prediction Laura J. Van ‘t Veer The Netherlands Cancer Institute, Amsterdam.

Kovacs G et al. Proc ASH 2014;Abstract 23.

Childhood leukaemia in Great Britain: trends in incidence, survival and ‘cure’ Anjali Shah UK Association of Cancer Registries conference 30 September.

Agne Paner, MD Assistant professor of Medicine RUSH University Medical Center.

Hepatitis web study Hepatitis web study Boceprevir in Treatment Experienced RESPOND-2 Phase 3 Treatment Experienced Bacon BR, et al. N Engl J Med. 2011;364:

Surrogate End point for Prostate Cancer- Specific Mortality After RP or EBRT A D’Amico J Nat Ca Inst 95,

Interim Results of an International, Multicenter, Phase 2 Study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in Relapsed or Refractory.

MANAGEMENT OF MANTLE CELL LYMPHOMA IN TUNISIA R BEN LAKHAL, L KAMMOUN, K ZAHRA, S KEFI Sousse 25 MAY 2012.

Very Bright Worship Service Facts to Break Sickle Silence ® September , 2010.

Multiple Sclerosis. Incidence 85,000 patient in UK Cases present between 20-40yrs of age Twice as many females Not a fatal condition, most patients have.

High Cereblon Protein Expression Correlates with Improved Response and Survival in Myeloma Patients Treated with Lenalidomide 1 Cereblon Expression Predicts.

5-Azacitidine For Myelodysplasia Before Allogeneic Hematopoietic Cell Transplantation Field T et al. Bone Marrow Transplant 2009:[Epub ahead of print].

R-CHOP vs R-FC Followed by Maintenance with Rituximab vs Interferon-Alfa in Elderly Patients with Mantle Cell Lymphoma Kluin-Nelemans HC et al. Proc ASH.

Alternating Courses of CHOP and DHAP Plus Rituximab (R) Followed by a High-Dose Cytarabine Regimen and ASCT is Superior to Six Courses of CHOP Plus R Followed.

CE-1 IRESSA ® Clinical Efficacy Ronald B. Natale, MD Director Cedars Sinai Comprehensive Cancer Center Ronald B. Natale, MD Director Cedars Sinai Comprehensive.

Reduced-Intensity Conditioning (RIC) and Allogeneic Stem Cell Transplantation (allo-SCT) for Relapsed/Refractory Hodgkin Lymphoma (HL) in the Brentuximab.

A Phase II Study with Carfilzomib, Cyclophosphamide and Dexamethasone (CCd) for Newly Diagnosed Multiple Myeloma Bringhen S et al. Proc ASH 2013;Abstract.

Complete Hematological Molecular and Histological Remissions without Cytoreductive Treatment Lasting After Pegylated-Interferon -2a (peg-IFN-2a) Therapy.

A Randomized Phase II Study Comparing Consolidation with a Single Dose of 90 Y Ibritumomab Tiuxetan (Zevalin ® ) (Z) vs Maintenance with Rituximab (R)

Head-to-Head Comparison of Obinutuzumab (GA101) plus Chlorambucil (Clb) versus Rituximab plus Clb in Patients with Chronic Lymphocytic Leukemia (CLL) and.

Rituximab Maintenance versus Wait and Watch After Four Courses of R-DHAP Followed by Autologous Stem Cell Transplantation in Previously Untreated Young.

Rituximab plus Lenalidomide Improves the Complete Remission Rate in Comparison with Rituximab Monotherapy in Untreated Follicular Lymphoma Patients in.

High Response Rates to Crizotinib in Advanced, Chemoresistant ALK+ Lymphoma Patients 1 Crizotinib in Advanced, Chemoresistant Anaplastic Lymphoma Kinase-Positive.

Time to Secondary Resistance (TSR) After Interruption of Imatinib: Updated Results of the Prospective French Sarcoma Group Randomized Phase III Trial on.

Low Dose Decitabine Versus Best Supportive Care in Elderly Patients with Intermediate or High Risk MDS Not Eligible for Intensive Chemotherapy: Final Results.

Bortezomib (BTZ) and Panobinostat (PAN) Combination Is Effective in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) or NK/T-Cell Lymphoma.

Moskowitz CH et al. Proc ASH 2014;Abstract 673.

Rituximab Maintenance After Chemoimmunotherapy Induction in 1 st and 2 nd Line Improves Progression Free Survival: Planned Interim Analysis of the International.

Early Treatment of Relapsed Ovarian Cancer Based on CA125 Level Alone Versus Delayed Treatment Based on Conventional Clinical Indicators Results of the.

Hairy Cell Leukemia Variant Has Similar Survival to Classical Disease Despite Poorer Responses to Initial Therapy: A 30-Year Experience from Memorial Sloan.

The DVD Trial. Source Reinecke H, Fobker M, Wellmann J, et al. A randomized controlled trial comparing hydration therapy to additional hemodialysis or.

Case 297 Guilin Tang and Sa A. Wang Department of Hematopathology UT MD Anderson Cancer Center.

Daunorubicin VS Mitoxantrone VS Idarubicin As Induction and Consolidation Chemotherapy for Adults with Acute Myeloid Leukemia : The EORTC and GIMEMA Groups.

P Ferguson, R Hills, A Grech, L Kjeldsen, M Dennis, P Vyas, R Clark, N Russell, C Craddock, On behalf of the NCRI AML Working Group. An operational definition.

Hepatic Steatosis in patients with Autoimmune Hepatitis (AIH) – prevalence, progression and possible significance C. Salmon*1, B.Hoeroldt2, A. Dube3,

Immunotherapy with CD19 CAR redirected T-cells for high risk, relapsed paediatric CD19+ acute lymphoblastic leukaemia (ALL) and other haematological malignancies.

Vose JM et al. Proc ASH 2011;Abstract 661.

DiNardo C et al. Proc ASH 2015;Abstract 327.

DEPRESSION AND FAMILY RELATIONSHIPS

CORAL Trial design: Patients with renal artery stenosis and hypertension or chronic kidney disease were randomized to renal artery stenting (n = 467) vs.

Discussion and Conclusions Acknowledgements and References

Presented By Luca Malorni at 2017 ASCO Annual Meeting

Goede V et al. Proc ASH 2014;Abstract 3327.

Dunleavy K et al. Proc ASH 2015;Abstract 472.

In Stem Cell Transplantation by Limiting the Morbidity of Graft-versus-Host Disease Tolerance to Myeloablative Conditioning is Improved Nicolas Novitzky,

R-CHOP Stem Cell Transplantation for Follicular Lymphoma

Coiffier B et al. Proc ASH 2010;Abstract 857.

Allogeneic Stem Cell Transplantation for Relapsed or Refractory Lymphoma after Conditioning with BEAM/Fludarabine/TBI Alix O’Meara, Jörg Halter, Dominik.

Vitolo U et al. Proc ASH 2011;Abstract 777.

CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma by Robert Marcus, Kevin Imrie, Andrew Belch,

Autoimmune hepatitis: A life-long disease

The Road to Quality Improvement in HER2-Positive Breast Cancer

Forero-Torres A et al. Proc ASH 2011;Abstract 3711.

Zaja F et al. Proc ASH 2010;Abstract 966.

Wiestner A et al. Proc ICML 2013;Abstract 008.

Clinical Challenges in the Patient With Relapsed Multiple Myeloma

Response to cyclosporin A (CsA) treatment and renal outcome in patients with either nongenetic or genetic disease. Response to cyclosporin A (CsA) treatment.

Mean changes (standard error) from baseline in A1C (A and B) and body weight (C and D) for patients with type 1 (A and C) or type 2 (B and D) diabetes.

Cox regression analysis of the proportion of patients remaining in remission during azathioprine treatment related to diagnosis of inflammatory bowel disease.

Genomic determinants of response to cytotoxic chemotherapy.

Cox regression analysis of the proportion of patients remaining in remission after stopping azathioprine treatment related to diagnosis of inflammatory.

Survival, subsequent therapies, and response.

Limited clinical relevance of imaging techniques in the follow-up of patients with advanced chronic lymphocytic leukemia: results of a meta-analysis by.

Single-site disease progression after 9 months of response to therapy in the right hemipelvis visualized by diffusion-weighted whole-body MRI. Top, fusion.

Presentation transcript:

HCL Patient Seminar September 2014 Quality of Life Monica Else

Quality of life in chronic lymphocytic leukaemia Large trial of 777 patients from 136 centres in Argentina, Croatia, Greece, Ireland, Italy, New Zealand, Russia, UK Comparing 3 different treatments Self-assessed quality of life questionnaire 5-year follow-up

Quality of life in chronic lymphocytic leukaemia – results Else et al, Leuk Lymphoma, 53: ; 2012 The coloured boxes denote a statistically significant difference between groups (10 points or more, p<0.01)

Quality of life in leukaemia: the long term

What are the implications for HCL?

Duration of remission in HCL Dearden et al, Leuk Lymphoma, 52(S2): 21-24; 2011

How do you make sure you have a CR? Bone marrow biopsy Further treatment if only a PR

Conclusions Having severe symptoms at the outset does not predict poor quality of life in the longer term Disease progression and relapse are associated with poor quality of life Long-term remission equates with good quality of life (“getting your life back”) and should be the aim of therapy